無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のインスリングラルギン市場の分析:2010年〜2019年

Investigation Report on China Insulin Glargine Market, 2010-2019

発行 China Research and Intelligence 商品コード 331521
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
中国のインスリングラルギン市場の分析:2010年〜2019年 Investigation Report on China Insulin Glargine Market, 2010-2019
出版日: 2015年05月28日 ページ情報: 英文 30 Pages
概要

インスリングラルギンは、組み換えDNA技術のシミュレーションによって作られた最初の長時間作用型インスリンです。米国では、最も広く使用されているインスリンとなっています。

当レポートでは、中国のインスリングラルギン市場について調査分析し、市場規模、市場シェア、小売価格、主要メーカー、市場見通しなどについて、体系的な情報を提供しています。

第1章 インスリングラルギンの関連概念

  • 適応
  • 世界市場の発展

第2章 中国のインスリングラルギン市場のプロファイル

  • 特許・認可の状況
  • 主要メーカー
  • 市場規模

第3章 中国のインスリングラルギンの売上高分析

  • 総売上高
  • 地域別の売上高

第4章 中国のインスリングラルギンの売上数量分析

  • 総売上数量
  • 地域別の売上数量

第5章 中国のインスリングラルギン主要メーカーの市場シェア分析

  • 市場シェア:売上高別
  • 市場シェア:売上数量別

第6章 中国のインスリングラルギンの剤形別の市場規模分析

  • 市場シェア (剤形別) :売上高別
  • 市場シェア (剤形別) :売上数量別

第7章 中国のインスリングラルギンの病院向け基準価格

第8章 中国のインスリングラルギン市場の主要メーカー

  • Gan & Lee Pharmaceuticals
  • Aventis Behring GmbH
  • Tonghua Dongbao Pharmaceutical Co., Ltd

図表

目次
Product Code: 1505183

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

Insulin glargine is the first long-acting insulin produced by simulating recombinant DNA technology. It was approved to be put into use by FDA in Apr. 2000 and then by the European Agency for the Evaluation of Medicinal Products (EMEA) in Jun. 2000. Since insulin glargine reports no obvious peak after using it for a long time, it has become the most widely-used insulin in the USA.

In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition.

According to CRI's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014-2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in Feb. 2015, the global market structure is estimated to change in the next few years. On Sep.9, 2014, Eli Lilly and Company and Boehringer-ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in Chinese market, some local enterprises are also hastening the development of Lantus's generic drug.

With the improvement of living standards and the change of life styles in China, the incidence of diabetes has kept growing and the market size of diabetes drugs has expanded each year, exceeding CNY 20 billion in 2014 according to CRI's research. Currently in China, the second generation of recombinant human insulin is the mainstream of market. Having reduced the defects of the second generation of insulin and effectively shortened the length of treatment, the third generation of insulin products is expected to substitute the second generation gradually. It is predicated that insulin glargine is a potential product of growth among all three generations of insulin products.

Readers can get at least the following information through this report:

  • market size of insulin glargine in China
  • market share of insulin glargine manufacturers in sample hospitals in China
  • retail price of insulin glargine in Chinese market
  • major manufacturers of insulin glargine in Chinese market
  • market outlook of insulin glargine in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antidiabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Insulin Glargine

  • 1.1. Indication
  • 1.2. Developments in Global Market

2. Market Profile of Insulin Glargine in China

  • 2.1. Patent and License Status
  • 2.2. Major Manufacturers
  • 2.3. Market Scale

3. Research on Insulin Glargine's Sales Value in China, 2010-2014

  • 3.1. Overall Sales Value
  • 3.2. Regional Sales Value

4. Research on Insulin Glargine's Sales Volume in China, 2010-2014

  • 4.1. Overall Sales Volume
  • 4.2. Regional Sales Volume

5. Research on Market Share of Major Manufacturers of Insulin Glargine in China, 2010-2014

  • 5.1. Market Share by Sales Value
  • 5.2. Market Share by Sales Volume

6. Research on Market Size of Dosage Forms of Insulin Glargine in China, 2010-2014

  • 6.1. Market Share of Different Dosage Forms by Sales Value
  • 6.2. Market Share of Different Dosage Forms by Sales Volume

7. Reference Price of Insulin Glargine in Chinese Hospitals

  • 7.1. Insulin Glargine produced by Beijing Gan & Lee
  • 7.2. Aventis Behring GmbH
  • 7.2. Aventis Behring GmbH
  • 7.3. Tonghua Dongbao

8. Major Manufacturers of Insulin Glargine for Chinese Market, 2010-2014

  • 8.1. Gan & Lee Pharmaceuticals
  • 8.2. Aventis Behring GmbH
  • 8.3. Tonghua Dongbao Pharmaceutical Co., Ltd

Selected Charts

  • Chart Patent Information of Related Drugs of Insulin Glargine in China
  • Chart Approval Status of Insulin Glargine in China
  • Chart Sales of Insulin Glargine in China, 2010-2014
  • Chart Sales Value of Insulin Glargine in China, 2010-2014
  • Chart Sales Value of Insulin Glargine by Regions in China, 2010-2014
  • Chart Sales Volume of Insulin Glargine in China, 2010-2014
  • Chart Sales Volume of Insulin Glargine by Regions in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Insulin Glargine by Sales Value in China, 2010-2014
  • Chart Sales Volume and Market Share of Insulin Glargine Made by Tonghua Dongbao, 2010-2014
  • Chart Retail Price of Insulin Glargine Made by Beijing Gan & Lee in Chinese Market in 2014
  • Chart Price of Insulin Glargine (LANTUS) Made by CSL Behring Gmbh (Germany) in China In 2014
Back to Top